SCHEDULE 1 – MBPRP

Medulloblastoma Preclinical Ribociclib and Paxalisib (MBPRP) Data Set Publications Policy

The MBPRP dataset comprises medulloblastoma group 3 (G3 MB) and medulloblastoma Sonic hedgehog (SHH MB) patient-derived-orthotopic xenografts (PDOX). These human tumor models were treated with either ribociclib (CDK4/6 inhibitor), paxalisib (PI3K/mTOR inhibitor), or the combination of these two drugs in comparison to control (vehicle). The key objective of this dataset is to validate the synergistic effect of the combination treatment observed *in vitro*, and evaluate the impact of these treatments on gene expression/pathways at the transcriptional level in MB.

The MBPRP Data Access Committee anticipates that data generated from the project will be used by other researchers (scientists who are employed by, or a student enrolled at or legitimately affiliated with, an academic, non-profit, or government institution, or a commercial company) to develop new analytical methods, validate results, and identify additional genetic variatons, alterations, associations, and correlations in the data.

Authors who use data from the project must acknowledge the MBPRP using the following wording "This study makes use of data generated by the Medulloblastoma Preclinical Ribociclib and Paxalisib Data Set of St. Jude Children's Research Hospital" and cite the primary MBPRP publication (see end of schedule).

Users should note that the MBPRP Data Access Committee bears no responsibility for the further analysis or interpretation of these data, over and above that published by the MBPRP.

Primary MBPRP publication:
Jonchere B, Williams JS, Liu J et al. Combination of CDK4/6 with BET-bromodomain and PI3K/mTOR inhibitors in medulloblastoma *in vitro* and *in vivo*. *Molecular Cancer Theraputics*. (Manuscript in revision).